Depression and the Link with Cardiovascular Disease

Arup K. Dhar1,2,3* and David A. Barton1,2,3

1Human Neurotransmitters Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia, 2 Alfred Psychiatry, Alfred Health, Melbourne, VIC, Australia, 3 Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia

This review provides an outline of the association between major depressive disorder (MDD) and coronary heart disease (CHD). Much is known about the two individual clinical conditions; however, it is not until recently, biological mechanisms have been uncovered that link both MDD and CHD. The activation of stress pathways have been implicated as a neurochemical mechanism that links MDD and CHD. Depression is known to be associated with poorer outcomes of CHD. Psychological factors, such as major depression and stress, are now known as risk factors for developing CHD, which is as important and is independent of classic risk factors, such as hypertension, diabetes mellitus, and cigarette smoking. Both conditions have great socioeconomic importance given that depression and CHD are likely to be two of the three leading causes of global burden of disease. Better understanding of the common causal pathways will help us delineate more appropriate treatments.

Keywords: depression, coronary heart disease, cardiac risk, cardiovascular disease, major depressive disorder

The known major links between CHD and MDD are outlined in this review. The search terms “depression, major depressive disorder, coronary heart disease, cardiac risk, cardiovascular disease,” were entered into an electronic database, “PubMed.” Articles published between 1950 and 2015, and written in English were chosen. Abstracts were then hand screened for relevance and were selected on the basis of addressing mechanisms associating MDD and CHD.

DEPRESSION AND CORONARY HEART DISEASE PREVALENCE

Major depression is a debilitating condition that presents with a number of cognitive and biological symptoms, including a pervasively lowered mood, anhedonia, negative cognitions, anergia, and appetite disturbance, and at its worst can manifest itself with suicidal thoughts and acts and psychotic features (1). The lifetime prevalence rates of major depression are in the order of 17%. It is known that major depression is more prevalent in people who have suffered a major cardiac event, with up to 40% of patients meeting the criteria for major depressive disorder (MDD) (2). The large European Action on Secondary Prevention through Intervention to Reduce Events (EUROASPIRE) study showed potentially even higher rates with up to 35% of men and up to 65% of women measured as having depression on the hospital anxiety and depression scale (3). The enhancing recovery in coronary heart disease (ENRICHD) trial looked at patients who had recently suffered a myocardial infarction (MI), and depression was diagnosed in 74% of them (4). If we look at figures from the community through to those who are hospitalized, we see rates of depression of 10% in general practice clinics (5, 6), which then increases to up to 30% in those with coronary heart disease (CHD) in outpatient clinics (5–8), and up to a staggering 50% in those who are an inpatient for coronary artery bypass surgery (6, 9).
The leading cause of mortality in the developed world is coronary artery disease (CAD). When cardiac disease and major depression present together, the prognosis for both worsen (10–12). Reviews have continually shown that major depression is associated with poorer quality of life (13) and increased morbidity (14–16) and mortality (7–9, 17, 18). If MDD is present at baseline in a CHD patient, then it is an independent risk factor for poorer cardiovascular outcomes including MI (16).

A meta-analysis of 11 studies showed that MDD conferred an overall relative risk of 1.64 for developing CHD (19). The severity of the depression is proportional to the risk of developing CAD (20). Regarding mortality, MDD confers a relative risk of 1.8 in those suffering comorbid CHD (21). For those who have suffered a MI, the presence of MDD is a bad prognostic factor and carries a five times increased risk of cardiac mortality within 6 months (22).

**MECHANISMS OF MAJOR DEPRESSION AND INCREASED CARDIAC RISK**

It has long been accepted that there are numerous behavioral and lifestyle factors at play that confers increased CHD risk in those suffering depression. Psychological stress experienced by people suffering from MDD can also cause deregulation in the sympathetic nervous system and hypothalamic–pituitary–adrenal (HPA) axis (23, 24) (see Figure 1). This in turn has a number of deleterious downstream effects, including the development of hypertension, left ventricular hypertrophy (25), coronary vasoconstriction, endothelial dysfunction (26–28), platelet activation, and the production of pro-inflammatory cytokines (29, 30) (see Table 1). The potential consequence of this is an elevated risk in ventricular arrhythmias (31) and MI (32).

**BEHAVIOURAL AND LIFESTYLE FACTORS**

It is well established that there are number of behavioral and lifestyle factors, which are present in MDD patients that can increase the chance of developing CHD (40). These include increased rates of smoking, alcohol intake, physical inactivity, and obesity (33). As seen with other medical conditions, major depression predicts poorer adherence responses in CHD patient to medications (41), lifestyle (42–44), and rehabilitation programs (45). In fact, non-completion rates in cardiac rehabilitation have been shown to be in the order of 44% compared to 29% in the non-depressed group (46). Therefore, we are likely to see the depressed CHD patient being less motivated and adherent to cardiac rehabilitation programs. MDD also makes it less likely to engage in lifestyle modification after a major cardiac event to reduce the classic risk factors of CHD. We see this with regards to cigarette smoking, where MDD patients are less likely to give up smoking and there consumption is also heavier (47).

**DISTURBANCE IN AUTONOMIC NERVOUS SYSTEM**

It has long been known that “stress” and heart disease are linked (10, 48). Stressful events, such as terrorist attacks (49), natural disasters (50), and even high stakes knockout soccer matches, have been positively associated with an increase in acute cardiovascular events (51). Mental stress is one of the many cognitive symptoms that people with major depression suffer from. Laboratory mental stress tests have been shown to activate sympathetic nervous outflow in the non-cardiac patient setting (52). The cardiac sympathetic nerves are preferentially activated by such mental stress (11). In animal models and the clinical setting (31, 53),

---

**FIGURE 1** | Possible mechanisms whereby depression confers elevated cardiac risk. This is likely to be multifactorial including sympathetic activation, hypothalamic–pituitary activation, endothelial dysfunction, platelet activation, proinflammatory cytokines, and atherosclerosis development along with cardiac vascular and rhythm abnormalities.
TABLE 1 | Summary of main findings in mechanisms of MDD and cardiac risk.

| Reference                  | Objective                                                                 | Subjects | Methods                                                                 | Results                                                                                     |
|----------------------------|---------------------------------------------------------------------------|----------|-------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Stapelberg et al. (33)     | To identify a model of causal mechanisms that link major depressive disorder to cardiovascular heart disease | –        | A comprehensive literature review                                       | Mechanisms linking MDD and CHD that are often discussed in the literature are genetic, behavioral, and immunological. As well as coagulation, omega-3 PUFAs deficiency and vascular endothelial dysfunction. However, rather than discussing them separately, these mechanisms should be viewed as interdependent networks. |
| Eyster et al. (23)         | To examine the sympathetic nervous system function in depression          | 11 depressed patients 8 patients with other psychiatric diagnosis 17 healthy subjects | Tritiated norepinephrine was used to observe the rate of norepinephrine spill over. Removal of norepinephrine from plasma was performed to assess the neuronal uptake of norepinephrine | Norepinephrine spill over was elevated in 5 of the 11 patients with depressive illness. Rapid removal phase of norepinephrine from plasma corresponded in patients with depression, suggesting increased neuronal uptake |
| Carney et al. (34)         | To examine whether depressed patients with coronary artery disease (CAD) have lower heart rate variability compared with non-depressed CAD patients | 19 depressed CAD patients 19 non-depressed CAD patients | Patients underwent 24-h Holter monitoring, with SD of normal-to-normal intervals used as the primary index of heart rate variability | Heart rate variability was significantly lower in non-depressed CAD patients. |
| Spieker et al. (35)        | To identify the mechanisms behind endothelial functioning in response to mental stress | 23 healthy subjects | Nitroglycerin and flow-mediated dilation (FMD) induced vasodilation were examined pre- and post-stress. FMD was also examined during stress | Endothelium-dependent vasodilation decreased by half in comparison to endothelium-independent vasodilation to nitroglycerin which remained unaffected. Intra-arterial infusion of norepinephrine for a similar duration of mental stress did not hinder FMD |
| Schlaich et al. (39)       | To determine possible mechanisms leading to sympathetic augmentation in hypertension | 22 hypertensive patients 11 normotensive patients | Microneurography and radio tracer dilution were used to measure regional sympathetic activity | Patients with hypertension demonstrated reduced neuronal norepinephrine reuptake, which in turn was associated with sympathetic activation in hypertension |
| Dinan (36)                 | To review the biological markers of depression, specifically neuroendocrine disturbances and the hypothalamic-pituitary-adrenal axis (HPA) | –        | A comprehensive literature review                                       | Numerous studies have demonstrated that MDD results from activation from the HPA. Other biological markers may be secondary to high glucocorticoid levels. |
| Wong et al. (37)           | To examine centrally directed norepinephrine and corticotropin-releasing hormone (CRH) secretion in medication-free patients with melancholic depression | 10 depressed patients 14 healthy subjects | Norepinephrine and CRH were measured in lumbar cerebrospinal fluid every 30 h in addition to plasma adrenocorticotropic hormone and cortisol secretion | Depressed patients had significantly higher levels of norepinephrine and plasma cortisol yet normal levels of CRH. There was a negative correlation between plasma cortisol and CRH in healthy patients, while there was no relationship demonstrated in the depressed group |
| Barton et al. (38)         | To assess the significance of the sympathetic nervous system in the promotion of cardiac risk in patients with MDD | 39 depressed patients 76 healthy subjects | Whole-body cardiac sympathetic activity was measured using noradrenaline iso柴 emulation methods and sympathetic nerve recording techniques | A bimodal distribution for whole body and heart sympathetic activity was demonstrated in patients with MDD. This subset of MDD patients had significantly high sympathetic activity |
| Ghiadoni et al. (27)       | To explore whether mental stress promotes atherogenesis via the impairment of endothelium-dependent vascular homeostasis in preclinical subjects | 8 non-insulin-dependent diabetic patients 10 healthy subjects | Response to sublingual glyceryl trinitrate and brachial artery flow-mediated dilation (FMD) were measured before and after a mental stress test. It was measured again in the healthy group, without a stress stimulus on a separate occasion | In healthy subjects, mental stress had no effect on the response to sublingual glyceryl trinitrate; however, FMD significantly reduced after. Without the stress stimuli, FMD was unchanged. While the diabetic group had lower FMD in comparison to controls, there were no changes following the stimuli for both FMD and sublingual glyceryl trinitrate responses |
| Brown et al. (6)           | To review the associations between MDD and CHD and address the clinical implications for treatment | –        | A comprehensive literature review                                       | While there is no evidence that treatment of depression will reduce this effect, it is still important to improve quality of life for those with depression through the benefits of psychological and pharmaceutical intervention |
| Poole et al. (39)          | To review the relationship between depression and adverse outcomes from acute coronary syndrome (ACS) and coronary artery bypass graft (CABG) surgery patients | –        | A comprehensive literature review                                       | Inflammation is a frequent causal process involved in the development of depressive symptoms and for adverse cardiac outcomes |
the significance of the activation of cardiac sympathetic cardiac fibers has demonstrated disturbances in heart rhythm, leading to increased risk of ventricular arrhythmias, decreased blood flow (54), left ventricular hypertrophy (25), and MI and sudden death (28). It has been shown that in depressed CHD patients, there is an elevated resting heart rate, and this also may be due to sympathetic hyperactivity in this group of patients (34).

Thus, it is postulated that the lowered removal of noradrenaline from the cardiac sympathetic synapse enhances the sympathetic stimulation and as a consequence confers CHD risk (38). In fact, it has been shown that there is a bimodal distribution of noradrenaline spill over in patients with MDD, with approximately one-third of patients exhibiting remarkably high levels (38). Interestingly, it has been shown that there is an elevated serotonin turnover in MDD patients who have not yet been treated with antidepressants, which is associated with the short allele of the serotonin transporter (55). This short allele has been also associated with increased urinary noradrenaline levels and therefore sympathetic over activity (56).

Hypertension is an established risk factor for the development of CHD. Up to 90% of patients with heart failure suffer from hypertension (28). Essential hypertension is often triggered and maintained by mental stress. The processes here include reduced uptake of noradrenaline (35) and activation of brain noradrenergic pathways and noradrenaline release from the heart. It has been demonstrated that there is indeed elevated noradrenaline levels in depressed patient’s plasma and cerebrospinal fluid (57). We have seen other psychogenic causes of hypertension with the well-known depressed patient’s plasma and cerebrospinal fluid (57). We have seen other psychogenic causes of hypertension with the well-known phenomenon of white coat hypertension, which persists after numerous visits (58), where you would traditionally expect some form of desensitization to occur and blood pressures to normalize.

With regards to the parasympathetic system, a further possible mechanism linking MDD and CHD includes heart rate variability as a marker of vagal activity (59). Decreased heart variability (60–62) is associated with post-infarct mortality (63–66). Heart rate variability is modulated by the cardiac vagus and has been described in MDD patients (10).

DISTURBANCE OF THE HYPOTHALAMIC–PITUITARY–ADRENAL AXIS

Major depressive disorder has been implicated in the stress-induced activation of the HPA axis (36). Elevated levels of cortisol have repeatedly been found in MDD patients (37, 67, 68). This hypercortisolemia causes an increased risk of a metabolic syndrome type state, which includes glucose intolerance, hyperlipidemia, and increased visceral fat mass (69–71). This metabolic syndrome not only confers a higher risk of cardiovascular disease (72) and diabetes (73) but has also been shown to drive sympathetic activation (74).

PLATELET, INFLAMMATORY AND AUTOIMMUNE MECHANISMS

Stress and anxiety, both common symptoms of major depression, can contribute to atherosclerosis (38). Increased platelet activation and endothelial dysfunction have been implicated as a potential pathophysiological pathway linking MDD and CHD (75, 76).

Prolonged mental stress, which is commonly experienced in those suffering from major depression, has been shown to induce prolonged endothelial dysfunction (27, 28). This endothelial dysfunction has been shown to be one of the early signs of future cardiovascular deterioration (77). In fact, oxidative stress itself has been described in numerous psychiatric illnesses (78).

Antiplatelet medication, such as aspirin, has long been a mainstay of preventative treatment of CHD (79). As stated, depression has been implicated with increased platelet reactivity (80), which will increase the relative risk of thrombus formation and arterial occlusion (10). MDD is associated with raised platelet serotonin levels, which promotes clotting (81). Further evidence of platelet activation can be shown by elevated levels of beta-thromboglobulin, which are raised in depressed CHD patients (80). It is this prothrombotic state, which leads to thrombus formation and consequently myocardial ischemia (17).

Inflammatory pathways have been proposed as one of the causal pathways responsible for MDD caused increased CHD risk (39), via atherosclerosis (82). Depressed patients have been found to have elevated levels of inflammatory markers, such as C-reactive protein (CRP), and proinflammatory cytokines, such as interleukin 1, 2, 6, and tumor necrosis factor (83–87). A number of these inflammatory markers have also been consistently associated with poor cardiovascular outcomes (88), and CRP can predict MI (89).

IMPLICATIONS FOR TREATMENT

Once major depression is present in those who have had a major cardiac event, we can expect them to still be suffering from depressive symptoms 4 months post discharge from hospital (90). It is important to recognize depression in CHD, yet the majority of cases are not diagnosed or managed accordingly (91). In a consensus statement from the National Heart Foundation of Australia, they recommended that routine screening for depression is carried out for all patients suffering from CHD and first presentation and at follow-up (92). A perceived barrier to screening for depression by clinicians is lack of time (93). A quick and simple way to screen for depression in this setting would be to use a validated rating scale, such as the Cardiac Depression Scale (94).

The onset of a major depression has been shown to negatively moderate treatment outcomes for CHD patients (95). A recent Cochrane review showed that antidepressant medication was superior to placebo in the treatment of major depression in those who are also physically unwell.

Of the various antidepressants available to treat MDD, it is not known which is the best to lower the risk of CVD events in those suffering MDD (96). Common side effects of antidepressants must be taken into consideration when prescribing in those depressed CHD patients. This includes dizziness, appetite changes, sleep disturbance, gastrointestinal side effects, and sexual side effects.

Selective serotonin reuptake inhibitors (SSRIs) are the first-line pharmacotherapy for the treatment of major depression. This is generally because of their tolerability and safety.
profile (97, 98) and are deemed to be safe in the cardiac setting (6, 99). The SSRIs have been shown to have a meaningful effect on major depression (100). The Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) demonstrated that the antidepressant sertraline improved depression in those who had suffered acute coronary syndrome (ACS) (101). The safety and efficacy of sertraline in the CHD group was evidenced in this study (101). The ENRICHD trial showed that antidepressant treatment improved CHD prognosis (102). In the review by (103), it was shown that antidepressant medication can positively alter physiological pathways linking MDD and CHD. We have stated that sympathetic over activity is important in causality of CHD, and reductions in sympathetic activity have been shown following SSRI treatment (104). However, SSRIs are not without their flaws, and it has been noted that some induce weight gain and metabolic abnormalities (105–109).

There are various classes of antidepressants, such as the aforementioned selective SSRIs, tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). They are equally as efficacious (110), but differ significantly in their receptor and this side effect profiles. The TCAs and MAOIs are generally avoided in the treatment of major depression in those who have comorbid cardiac conditions, because of their toxic cardiac side effects (111). TCAs have been associated with elevated relative risk of 1.24 for CHD (112) and increased mortality rates in CHD (113). TCAs are also also highly toxic in overdose (114), which is of concern to the prescribing clinician especially when treating those with a history of suicidal behavior. TCAs can cause QTc prolongation (115) and decrease heart rate variability (64) secondary to their anticholinergic effects.

With regards to psychological therapies for depression, such as cognitive behavioral therapy (CBT), they seem to be efficacious for the depression without being beneficial for CHD morbidity or mortality (116). The UK National Institute of Clinical Excellence's (NICE) guideline on depression in adults with chronic physical health problems advises that psychological treatment (such as CBT) be the first line of treatment for mild to moderate depression. A Cochrane review has indicated that moderate aerobic exercise in the order of 30 min, five times a week is beneficial for relieving MDD symptoms. The magnitude of its efficacy should not be dismissed as Cochrane showed it had similar efficacy to CBT (117), and it of course will be beneficial to one's cardiovascular health. In those who exercise, it can be seen that depression, quality of life, and global functioning scores improve, thus decreasing the intensity and longevity of the episode of MDD (118). In the cardiac rehabilitation, setting exercise programs has not only shown to be beneficial for depression scores but also improves body percentage fat, triglyceride, and cholesterol levels (119).

In relation to platelet function, we have already discussed that platelet hyperactivity leads to a prothrombotic state, which in turn leads to increased risk of CHD. The SADHART platelet substudy showed a decreased platelet activation in those patients who had suffered an MI, were depressed, and had it treated with a SSRI, namely, sertraline (101). Paroxetine has also been shown to decrease platelet hyperactivity (120, 121). SSRIs have been shown to decrease sympathetic hyperactivity and, as a consequence, potentially reduce cardiac morbidity and mortality (38).

CONCLUSION

The underlying mechanism linking MDD and CHD are complex and multifactorial. As discussed, they involve the sympathetic nervous system, platelet hyperactivity, inflammation, and HPA dysregulation among others. Given that a definitive mortality study is unlikely to be done due to the complexities and costs involved, we are therefore guided by current evidence to maximize efficacy and potential harm when choosing our treatments for MDD who have comorbid CHD. We should be considering MDD as a common and modifiable risk factor for CHD, just like we do for smoking, hypertension, hyperlipidemia, and the like. The toxic combination of MDD and CHD leads to poorer health outcomes for both conditions and escalating health-care costs. The implications for research is that further understanding of the pathophysiological mechanisms underpinning MDD and CHD is required so as to inform us of better treatments. It would be interesting to see not only studies looking at underlying biological mechanisms but also clinical ones. There needs to be an effort to try and minimize the barriers to screening and treating of MDD in those suffering from CHD. Given the bidirectionality of the conditions, it would also be useful to elucidate whether treatments for CHD can potentially decrease the intensity of symptom burden of MDD. Future clinical practice may include initiating cardioprotective medications alongside antidepressants when MDD is diagnosed, thus alleviating the morbidity, mortality, and cost burdens of MDD and CHD.

AUTHOR CONTRIBUTIONS

AD and DB made equal contribution to the preparation, revision and production of this review.

ACKNOWLEDGMENTS

The authors would like to thank Ms. Amy Lingard and Ms. Robyn Hemmes for their help in the preparation of this manuscript.

FUNDING

This study was funded by Baker IDI Heart and Diabetes Institute.
REFERENCES

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: Man-Mag (2013).

2. Celano CM, Huffman JC. Depression and cardiac disease: a review. Cardiol Rev (2011) 19:130–42. doi:10.1097/CRD.0b013e31820e1106

3. Kotsena K, Wood D, De Racker G, De Baquer P, Pyorälä K, Keil U, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil (2009) 16:121–37. doi:10.1097/HJR.0b013e328294b1d

4. Carney RM, Blumenthal JA, Freedland KE, Youngblood M, Veith RC, Burg MM, et al. Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom Med (2004) 66:466–74. doi:10.1097/01.psy.0000133362.73057.5a

5. Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res (2002) 53:849–57. doi:10.1016/S0022-3999(02)00304-5

6. Brown AD, Barton DA, Lambert GW. Cardiovascular abnormalities in patients with major depressive disorder. CNS Drugs (2009) 23:583–602. doi:10.2165/00022320-200923070-00004

7. Carney RM, Rich MW, Freedland KE, Saini J, Simeone CJ, Clark K. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med (1988) 50:627–33. doi:10.1097/00006842-198811000-00009

8. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation (1996) 93:1976–80. doi:10.1161/01.CIR.93.11.1976

9. Ziegelstein RC. Depression in patients recovering from a myocardial infarction. JAMA (2001) 286:1621–7. doi:jama.2001.286.1621

10. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry (1998) 55:580–92. doi:10.1001/archpsyc.55.5.580

11. Bunker SJ, Colquhoun DM, Eder MD, Hickie IB, Hunt D, Jelinek VM, et al. “Stress” and coronary heart disease: psychosocial risk factors. Med J Aust (2003) 178:272–6.

12. Rosengren A, Hawken S, Ôunpuu S, Sliwa K, Zubaid M, Almahmeed W A, et al. Multimorbidities and total mortality in a community sample. Circulation (2002) 106:201–10. doi:10.1161/01.CIR.0000058371.50240.E3

13. Rugulies R, Baumeister H, Balke K, Härter M. Psychiatric and somatic comorbidities among 146,538 participants in 54 observational studies. Eur J Heart (2006) 27:2763–74. doi:10.1016/j.ehjhe.33538

14. Dhar and Barton

15. Depression and Cardiovascular Disease

16. Lange-Asschenfeldt C, Lederbogen F. [Antidepressant therapy in coronary artery disease]. Nervenarzt (2011) 82:657–64. doi:10.1007/s00115-010-3181-7

17. Esler M, Turrott J, Schwarz R, Leonard P, Bobik A, Skews H, et al. The peripheral kinetics of norepinephrine in depressive illness. Arch Gen Psychiatry (1982) 39:295–300. doi:10.1001/archpsyc.1982.0429003005006

18. Veith RC, Lewis N, Linares OA, Barnes RF, Raskind MA, Villacres EC, et al. Sympathetic nervous system activity in major depression: basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry (1994) 51:411–22. doi:10.1001/archpsyc.1994.03950050071008

19. Schlaich MP, Kray DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation (2003) 108:560–5. doi:10.1161/01.CIR.0000081775.72651.B6

20. Rugulies R. The role of endothelin in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol (1993) 22:51–4. doi:10.1097/00005354-199332004-00002

21. Ghiadoni L, Donald AE, Croyele M, Mullen MJ, Oakley G, Taylor M, et al. Mental stress induces transient endothelial dysfunction in humans. Circulation (2000) 102:2473–8. doi:10.1161/01.CIR.102.20.2473

22. Speiker LE, Hürlimann D, Ruschitzka F, Corti R, Enselelf F, Shaw S, et al. Mental stress induces prolonged endothelial dysfunction via endothelin-A receptors. Circulation (2002) 105:2817–20. doi:10.1161/01.CIR.0000021598.15895.34

23. Brydon L, Edwards S, Jia H, Mohamed-Ali V, Zachary I, Martin JF, et al. Psychological stress activates interleukin-1β gene expression in human mononuclear cells. Brain Behav Immun (2005) 19:540–6. doi:10.1016/j.bbi.2004.12.003

24. von Kanel R, Kudielka BM, Preckel D, Hansbath D, Fischer JE. Delayed response and lack of habituation in plasma interleukin-6 to acute mental stress in men. Brain Behav Immun (2006) 20:40–8. doi:10.1016/j.bbi.2005.03.013

25. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med (1991) 325:618–24. doi:10.1056/NEJM199108293250905

26. Wissert IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP, Greenberg G, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med (2005) 353:539–48. doi:10.1056/NEJMoa040346

27. Stapelberg NJ, Neumann DL, Shum DH, McConnell H, Hamilton-Craig I. A topographical map of the causal network of mechanisms underlying the relationship between major depressive disorder and coronary heart disease. Aust N Z J Psychiatry (2011) 45:351–69. doi:10.3109/00048674.2011.570427

28. Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol (1995) 76:562–4. doi:10.1016/0002-9149(95)80155-6

29. Schlaich MP, Lambert E, Kray DM, Krozowski Z, Campbell DJ, Lambert G, et al. Symphathetic augmentation in hypertension role of norepinephrine, norepinephrine receptors, and angiotensin neumodulation. Hypertension (2004) 43:169–75. doi:10.1161/01.HYP.0000131610.35395.9E

30. Dinan TG. Glucocorticoids and the genesis of depressive illness. A psychobiological model. Br J Psychiatry (1994) 164:365–7. doi:10.1192/bjp.164.3.365

31. Wong M-L, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, et al. Pronounced and sustained central hyporeninemic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A (2000) 97:325–30. doi:10.1073/pnas.97.1.325

32. Barton DA, Dawood T, Lambert EA, Esler MD, Haikerdal W, Drenchely C, et al. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens (2007) 25:2117–24. doi:10.1097/01.HJH.0b013e328298baee7

33. Poole L, Dickens C, Stopeo A. The puzzle of depression and acute coronary syndrome: reviewing the role of acute inflammation. J Psychosom Res (2011) 71:61–8. doi:10.1016/j.jpsychores.2010.12.009

34. Joynt KE, Whellan DJ, O’Connor CM. Depression and cardiovascular disease: mechanisms of interaction. Biol Psychiatry (2003) 54:248–61. doi:10.1016/S0006-3223(03)00568-7

35. Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with coronary heart disease: findings from the
Depression and Cardiovascular Disease

61. Carney RM, Freedland KE, Stein PK, Skala JA, Hoffman P, Jaffe AS. Change in heart rate and heart rate variability during treatment for depression in patients with coronary heart disease. *Psychosom Med* (2000) 62:639–47. doi:10.1097/00006842-200009000-00007

62. Pitzalis MV, Iacovelli M, Todarello O, Fioletti A, Guida P, Massari F, et al. Depression but not anxiety influences the autonomic control of heart rate after myocardial infarction. *Am Heart J* (2001) 141:765–71. doi:10.1067/mhj.2001.114806

63. Kleiger RE, Miller JP, Bigger JT, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. *Am J Cardiol* (1987) 59:256–62. doi:10.1016/0002-9149(87)90795-9

64. Bigger JT, Fleiss JL, Steinman RC, Rolnitzy LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. *Circulation* (1992) 85:164–71. doi:10.1161/01.CIR.85.1.164

65. La Roveere MT, Bigger JT, Marcus FL, Mortara A, Schwartz PJ, Investigators A. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. *Lancet* (1998) 351:478–84. doi:10.1016/S0140-6736(97)31144-8

66. Walther T, Wessel N, Baumert M, Stepan H, Voss A, Faber R. Longitudinal analysis of heart rate variability in chronic hypertensive pregnancy. *Hypertens Res* (2005) 28:113–8. doi:10.1258/hyp.2005.28.113

67. Gold P, Chrousos G. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs. low CRH/NE states. *Mol Psychiatry* (2002) 7:254–75. doi:10.1038/sj.mp.4001032

68. Parker KI, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercorisolism in major depression. *Horm Behav* (2003) 43:60–6. doi:10.1016/S0018-506X(02)00116-8

69. Björntorp P. Neuroendocrine abnormalities in human obesity. *Metabolism* (1995) 44:38–41. doi:10.1016/0026-0495(95)90208-2

70. Björntorp P, Rosmond R. The metabolic syndrome – a neuroendocrine disorder? *Br J Nutr* (2000) 83:549–57. doi:10.1079/BJN200000957

71. Björntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. *Int. J Obes Relat Metab Disord* (2000) 24:580–8. doi:10.1038/sj.ijo.0801285

72. Malik S, Wong ND, Franklin SS, Kamath TV, Gilbert J, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascudial disease, and all causes in United States adults. *Circulation* (2004) 110:1245–50. doi:10.1161/01.CIR.0000104677.20606.EE

73. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). *Diabetes* (1992) 41:715–22. doi:10.2337/diabetes.41.6.715

74. Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. *Clin Endocrinol Metab* (2005) 90:5998–6005. doi:10.1210/jc.2005-09961

75. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). *Am Coll Cardiol* (2004) 44:671–719. doi:10.1016/S0735-1097(04)50116-8

76. Hoffmann MM, Guevara J, Angers H, Silver M, Silverman M, Harper S, et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. *J Affect Disord* (1995) 34:301–9. doi:10.1016/0165-0327(95)00028-I

77. Lerman A, Zeiher AM. Endothelial function cardiac events. *Circulation* (2005) 111:363–8. doi:10.1161/01.CIR.0000153339.27064.14

78. Chauvet-Gélinrier J-C, Trojak B, Vergés-Patios B, Cottin Y, Bonin B. Review on depression and coronary heart disease. *Arch Cardiovasc Dis* (2013) 106:103–10. doi:10.1016/j.acvd.2012.12.004

79. Nemeroff CB, Muselman DL. Are platelets the link between depression and ischemic heart disease? *Am Heart J* (2000) 140:557–62. doi:10.1067/mhj.2000.109978

80. Laghrissi-Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and β-thromboglobulin plasma levels in depressed patients
Dhar and Barton

Depression and Cardiovascular Disease

with ischemic heart disease. *Biol Psychiatry* (1997) 42:290–5. doi:10.1016/S0006-3223(96)00345-9

81. Santer EJ, Frasure-Smith N, Lespérance F. Reflections on depression as a cardiac risk factor. *Psychosom Med* (2005) 67:S19–25. doi:10.1097/01.psyy.0000162523.07959.db

82. Frasure-Smith N, Lespérance F. Depression and coronary artery disease. *Cochrane Database Syst Rev* (2011) CD008012. doi:10.1002/14651858.CD008012.pub3

83. Serebruany VL, Glassman AH, Malinov AI, Nemeroff CB, Mussen DM, Van Zyl LT, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor paroxetine after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. *Circulation* (2003) 108:399–44. doi:10.1161/01.CIR.0000085163.21752.0A

84. ENRICHD Investigators. Enhancing Recovery in Coronary Heart Disease (ENRICHD) study intervention: rationale and design. *Psychosom Med* (2001) 63:747–55

85. Skala JA, Freedland KE, Carney RM. Coronary heart disease and depression: a review of recent mechanistic research. *Can J Psychiatry* (2006) 51:738.

86. Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, et al. Depression, heart rate variability, and acute myocardial infarction. *Circulation* (2001) 104:2024–8. doi:10.1161/hc4201.097834

87. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. *J Clin Psychiatry* (2000) 61:863–7. doi:10.4088/JCP.v61n109

88. Raeder MB, Bjelland I, Emil VS, Steen VM. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. *Am J Cardiol* (2006) 97:1742–8. doi:10.1016/j.amjcard.2006.11.041

89. Dannon PN, Iancu I, Cohen A, Lowengrub K, Grunhaus L, Kotler M. Three year naturalistic outcome study of panic disorder patients treated with paroxetine. *BMC Psychiatry* (2004) 4:16. doi:10.1186/1471-244X-4-16

90. Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. *J Clin Psychiatry* (2004) 65:1365–71. doi:10.4088/JCP.v65n1011

91. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. Meta-analysis: pharmacologic treatment of obesity. *Ann Intern Med* (2005) 142:532–46. doi:10.7326/0003-4819-142-7-20050405-00012

92. Pilling S, Anderson L, Goldberg D, Meader N, Taylor C. Depression in adults, including those with a chronic physical health problem: summary of NICE guidance. *BMJ* (2009) 339. doi:10.1136/bmj.b4108

93. Lichtman JH, Bigger JT, Blumenthal JA, Frawse-Smith N, Kaufmann PG, Lespérance F, et al. Depression and coronary heart disease recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. *Circulation* (2008) 118:1768–75. doi:10.1161/CIRCULATIONAHA.108.190764

94. Hamer M, Batty GD, Seldenrijk A, Kivimaki M. Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. *Eur Heart J* (2011) 32:437–42. doi:10.1093/eurheartj/ehq438

95. Witchel HJ, Hancock JC, Nutt DJ. Psychotropic drugs, cardiac arrhythmia, and sudden death. *J Clin Psychopharmacol* (2003) 23:58–77. doi:10.1097/00004714-200302000-00010

96. Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. *Acta Psychiatri Scand* (2008) 118:334–42. doi:10.1111/j.1600-0447.2008.01260.x

97. Follath F. [Depression, stress and coronary heart disease — epidemiology, prognosis and therapeutic sequelae]. *Ther Umsch* (2003) 60:697–701. doi:10.1024/0040-5930.60.11.697

98. Whalley B, Rees K, Davies P, Bennett P, Ebrahim S, Liu Z, et al. Psychological interventions for coronary heart disease. *Cochrane Database Syst Rev* (2011) 21:8. doi:10.1002/14651858.CD002902.pub3

99. Cooney GM, Dwan K, Greig CA, Lawlor DA, Rimmer J, Waugh FR, et al. Exercise for depression. *Cochrane Database Syst Rev* (2013) CD004366. doi:10.1002/14651858.CD004366.pub6

100. Rwanzu M, Begemann MJ, Heringa SM, Sommer IE. Exercise improves clinical symptoms, quality of life, global functioning, and depression in schizophrenia: a systematic review and meta-analysis. *Schizophren Bull* (2015) sbv164. doi:10.1093/schbul/sbv164
Conflict of Interest Statement: The Human Neurotransmitters Laboratory is currently receiving research funding from National Health and Medical Research Council of Australia and from Otsuka Pharmaceuticals. It has previously received research funding from Servier Pharmaceuticals. Dr. AD has received travel honoraria from Servier and Otsuka pharmaceuticals. Prof. DB has received honoraria for presentations from Eli Lilly, Servier, Pfizer, Solway Pharmaceuticals, Wyeth Pharmaceuticals, Lundbeck, and AstraZeneca. He has received research funding from Servier, Pfizer, Eli Lilly, Otsuka, and Lundbeck.

Copyright © 2016 Dhar and Barton. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.